Glycemic Targets and Cardiovascular Disease  

Oleh:

Cefalu, William T.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 24 (Jun. 2008), page 2633.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.03 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Cardiovascular disease in patients with diabetes is clearly associated with the degree of hyperglycemia, as measured clinically with the use of glycated hemoglobin.1,2,3 However, there remains an unanswered question in diabetes management: Does the targeting of near normal levels of glycated hemoglobin reduce the rate of cardiovascular events? Randomized clinical trials that address this question are ongoing. In this issue of the Journal, results are presented from two recently completed multicenter clinical trials, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial (ClinicalTrials.gov number, NCT00000620 [ClinicalTrials.gov] )4 and the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali